Introduction
Oligodendrogliomas are infiltrative tumors of the central nervous system (CNS). They constitute between 4 and 5% of the primary CNS tumors and 4 to 15% of the glial tumors. enhancement, suggestive of low-grade glioma (►Fig. 2). The patient was submitted to craniotomy and gross total resection (GTR) of the lesion (►Fig. Two years later, in imaging control, tumor growth was recorded in the posterior and medial portion of the surgical site. An MRI showed characteristics similar to the initial lesion, namely without evidence of contrast enhancement, During the 2nd cycle of chemotherapy, the patient presented with a new neurological deficit, a motor apraxia of the right upper limb. Another MRI was undertaken, which revealed tumor progression, with a recurrent tumor in the surgical site and still with left hemispheric meningeal dissemination revealing an extra-axial mass with contrast 25 and 26) . The neuropathological study of the various lesions was shown to be the same sarcomatous tumor, and complementary treatment with 2nd line chemotherapy (irinotecan with bevacizumab) was initiated. At the end of 2 months of treatment, the patient exhibited severe cervical radiculopathy without relief with analgesics, and was submitted to lumbar puncture, which showed the presence of malignant cells in the cerebrospinal fluid. He underwent a neuro-axis MRI, which showed stability of the disease at the brain but extensive spreading to the medulla with intradural and extramedullary lesions at the cervical and medullary cone levels (►Figs. 27, 28). He started treatment with 3rd line chemotherapy (lomustina 90 mg/m 2 for 6 days/week, for /6 weeks, and bevacizumab 10 mg/kg for 2 days/week for 2 weeks. The patient also performed 5 sessions of radiotherapy directed to the cervical lesion (5 fractional radiotherapy sessions totaling 20 Gy). Currently, the patient has a 4-year overall survival, with Karnofsky performance status of 60% and eastern cooperative oncology group (ECOG) performance status 2. Discussion Isocitrate dehydrogenase-mutated and 1p/19q-positive codeletion oligodendrogliomas are considered slow-growing tumors with a better prognosis than the other gliomas. 5 The appearance of sarcomatous tumors at sites of oligodendrogliomas resection in patients not undergoing further chemotherapy and/or radiotherapy treatments is very rare.
6
Although in most cases the glial component of the sarcomatous tumors is astrocytic, the literature describes several cases of gliosarcomas in which the glial component is oligodendrocytic.
2,3,6-10
Here, we describe the case of an oligodendroglioma WHO grade II with 1p/19q co-deletion, IDH-1 and ATRX mutation, with initial GTR, not subjected to complementary treatments, and which was dedifferentiated to the sarcomatous form. The tumor always maintained the same genetic characteristics. Despite the presence of predictive factors of better prognosis, the tumor displayed poor response to radiotherapy and chemotherapy, and even presented spinal metastasis. Although several cases have been described in the literature of oligodendrogliomas with transformation to the sarcomatous form (oligosarcoma), research performed in PubMed and Google Scholar reveals only one case with spinal metastasis.
8
Most cases with extracranial dissemination are associated with extensive progression of the brain tumor;
11 yet, in this case, the spread occurred with stability of the brain lesions. This case describes a patient with a low-grade glioma, with most of the predictive factors of better prognosis (age < 40 years, total initial resection and favorable genetics), in whom progression occurred rapidly and with refractoriness to complementary treatments.
Conclusion
Despite all the good prognostic factors present in this clinical case and the absence of previous adjuvant therapies, the tumor was dedifferentiated to a malignant form, quickly and without any warning signs.
This leads us to conclude that there is a need for further studies that may indicate new prognostic factors, such as imaging, anatomopathological and genetic characteristics that help us understand which tumors will dedifferentiate more quickly and which may respond better to complementary treatments.
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